Mixed Features After Antidepressant Monotherapy in a Woman Planning Pregnancy
A 36-year-old married woman with two children, working as a schoolteacher, is referred by her gynecologist. She has had four major depressive episodes since age 20. Three months ago sertraline was increased to 100 mg daily for a recurrent episode. In the past 3 weeks she has become increasingly irritable, sleeps 3 hours a night without fatigue, talks rapidly, and has started three online businesses and spent more than a monthly salary on them; her mood, she says, is still 'black'. On examination she is tangential but redirectable, with pressured speech and psychomotor restlessness. MADRS 26, YMRS 18. She has autoimmune hypothyroidism treated with levothyroxine 100 micrograms daily, TSH 4.8 mIU/L. She wants to become pregnant within the year and asks whether her medications are safe. She had one brief hypomanic episode at age 24 after fluoxetine, never treated with lithium.
1. What is the diagnosis, and why is continuing antidepressant monotherapy the wrong move here?
Read the worked answer
The pattern meets criteria for a major depressive episode with mixed features: a full depressive syndrome (MADRS 26) plus at least three manic/hypomanic symptoms - decreased need for sleep with only 3 hours, pressured speech, tangential thinking, increased goal-directed activity (three businesses), and reckless spending.
The critical historical point is the hypomanic switch at age 24 on fluoxetine, which makes a bipolar spectrum disorder far more likely than unipolar depression. Antidepressant monotherapy in this setting risks: (a) worsening the mixed state and inducing a full manic episode or rapid cycling; (b) increasing suicide risk, because mixed states carry among the highest suicide risk of any mood state - depressed mood plus agitation, energy and impulsivity is a dangerous combination; (c) promoting treatment resistance and confusing the longitudinal diagnosis.
Also consider alternatives and modifiers: sertraline activation is not the same as a mixed episode; hypothyroidism with TSH 4.8 mIU/L can worsen mood and should be corrected; and substance or steroid use should be excluded. Depending on severity and duration criteria, the diagnosis is bipolar I disorder, current episode mixed. This changes everything downstream: no antidepressant monotherapy, a mood stabilizer first, and careful counseling about recurrence and genetics.
2. Outline the pharmacologic plan, including the fact that she wants to conceive within a year.
Read the worked answer
Stop sertraline, tapering over 1-2 weeks rather than abruptly, and do not substitute another antidepressant. First-line options are lithium or quetiapine. In a mixed state with high energy, lithium has the best evidence for suicide prevention and long-term prophylaxis, but it requires baseline creatinine/eGFR, TSH, calcium, weight, and ECG if there is cardiac risk; target a level of 0.6-0.8 mEq/L.
Because she wants pregnancy within a year, discuss this now, not later. Lithium carries a small absolute teratogenic risk (cardiac Ebstein anomaly in roughly 1 in 1,000 exposed pregnancies versus about 1 in 20,000 unexposed), while the risk of stopping lithium and relapsing, particularly postpartum, is substantial. A defensible approach is to continue lithium at the lowest effective dose with level checks and fetal echocardiography at 18-20 weeks, or to switch before conception to lamotrigine (start 25 mg and titrate slowly because of Stevens-Johnson risk; remember that estrogen-containing contraceptives and pregnancy alter levels). Quetiapine 300-600 mg is a reasonable alternative if lithium is declined, with metabolic monitoring.
Treat the thyroid: continue levothyroxine, check free T4, and aim for a normal TSH, since hypothyroidism independently worsens mood. Use a benzodiazepine only briefly if agitation is severe, and document shared decision-making with the patient and her husband.
3. What would you monitor in the first 6 weeks and over the first year, and why?
Read the worked answer
Each drug and each mood state carries specific measurable risks, and the first weeks are the highest-risk window for rash, lithium toxicity, and suicide.
Mental state: weekly visits early on; ask directly about suicidal ideation, plan and access to means, about sleep, and about mixed symptoms; use a validated scale (YMRS and MADRS) at each visit rather than relying on impressions.
Lithium: a level 5-7 days after any dose change and 12 hours post-dose, then every 3-6 months once stable; creatinine/eGFR and TSH every 6-12 months, more often with interacting drugs; calcium and weight. Counsel on sodium and water balance, dehydration, NSAIDs and ACE inhibitors.
Metabolic: weight, blood pressure, fasting glucose and lipids at baseline and 3 months, especially if quetiapine is used.
Suicide risk: means restriction and a written crisis plan, because mixed states can worsen before they improve.
Reproductive: contraception counseling now, folic acid, and documentation that lithium and valproate are incompatible with an unplanned pregnancy.
Adherence: anticipate the wish to stop medication once she feels better, and address it in advance with the patient and her husband rather than after the next relapse.